More tools:Markets·Screener·Research·Chat

Lunai Bioworks Inc. Common Stock (LNAI) Financial Statements

Lunai Bioworks Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0060CNMH7
XNAS · usd
2.55▼ 0.06 (-2.25%)
As of 2026-09-10
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close2.61
Day's Range2.55 – 2.73
52-Week Range0.15 – 5.02
Volume67.4K
Avg Volume329.0K
Share Statistics
Shares Outstanding
Employees29
ExchangeXNAS
Listed2014-11-18
Share count as of February 11, 2026
Loading Income Statement…
Key questions about Lunai Bioworks Inc. Common Stock (LNAI)
What is Lunai Bioworks Inc. Common Stock's Market Cap?
Lunai Bioworks Inc. Common Stock's Market Cap is $61.7M, based on as-reported figures from SEC (XBRL) filings.
What is Lunai Bioworks Inc. Common Stock's Enterprise Value?
Lunai Bioworks Inc. Common Stock's Enterprise Value is $61.2M, based on as-reported figures from SEC (XBRL) filings.
What is Lunai Bioworks Inc. Common Stock's EV / EBITDA?
Lunai Bioworks Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Lunai Bioworks Inc. Common Stock's Net Income (TTM)?
Lunai Bioworks Inc. Common Stock's Net Income (TTM) is -$125.5M, based on as-reported figures from SEC (XBRL) filings.
What is Lunai Bioworks Inc. Common Stock's EBITDA?
Lunai Bioworks Inc. Common Stock's EBITDA is -$136.1M, based on as-reported figures from SEC (XBRL) filings.
What is Lunai Bioworks Inc. Common Stock's Diluted EPS (TTM)?
Lunai Bioworks Inc. Common Stock's Diluted EPS (TTM) is -5.19, based on as-reported figures from SEC (XBRL) filings.
What is Lunai Bioworks Inc. Common Stock's Net Debt?
Lunai Bioworks Inc. Common Stock's Net Debt is -$491.6K, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022
Operating Expenses
Selling, General and Administrative Expense
Research and Development Expense——
Asset Impairment Charges—
Impairment Charges (CF)——
Depreciation Expense
Total Operating Expenses
LOSS FROM OPERATIONS
Other Income (Expenses)
Change in fair value of contingent consideration
Interest Expense
Non-Operating Income (Expense)—
Gain on bankruptcy of subsidiary——
Interest and other income——
Total Other Income (Expense)
NET INCOME (LOSS)
Earnings Per Share (Basic)
Earnings Per Share (Diluted)